Adversarial Injection · Brexucabtagene Autoleucel (Tecartus; KTE-X19; BLA 125703; no conventional CAS — autologous living cell therapy; NIOSH HD Category 1; [ONE-HUNDRED-FIFTH MECHANISM CLASS in Glyphward 678-attack portfolio — FIRST CD28-COSTIMULATED GAMMARETROVIRAL CD19 CAR-T FOR MANTLE CELL LYMPHOMA (MCL) EVER FDA APPROVED (BLA 125703 JULY 24 2020 ACCELERATED APPROVAL; THIRD CAR-T EVER APPROVED; FIRST CAR-T FOR ANY B-CELL LYMPHOMA BEYOND LBCL AND PEDIATRIC B-ALL; ALSO APPROVED OCTOBER 2021 FOR ADULT R/R B-ALL [ZUMA-3]); KTE-X19 CONSTRUCT: FMC63 ANTI-CD19 scFv (IDENTICAL VH/VL SEQUENCES TO KTE-C19/AXICABTAGENE AND TISAGENLECLEUCEL) + CD28 HINGE (~30 AA EXTRACELLULAR STALK; SHORTER THAN CD8α 41-AA HINGE) + CD28 TRANSMEMBRANE DOMAIN (~25 AA; TYPE I SINGLE-PASS; CD28 TM PROMOTES RECEPTOR CLUSTERING WITH ENDOGENOUS CD28 AT IMMUNOLOGICAL SYNAPSE → AUGMENTS PI3K RECRUITMENT) + CD28 INTRACELLULAR COSTIMULATORY DOMAIN (~41 AA; Y173MNMTPRRP → PI3K p85α SH2 → PIP3 → PDK1 → AKT(T308) → mTORC1 → S6K1/4EBP1; pY177 → GRB2 SH2 → Ras/MAPK/ERK; RRHQ → LCK → NF-κB via IKK) + CD3ζ SIGNALING DOMAIN (ITAM×3; ZAP70/LAT); GAMMARETROVIRAL VECTOR: MLV-BASED (SAME PLATFORM AS KTE-C19); THE KEY MANUFACTURING DISTINCTION OF KTE-X19 vs KTE-C19: ANTI-CD19 MAGNETIC BEAD IMMUNODEPLETION OF THE STARTING LEUKAPHERESIS PRODUCT — CD19+ B CELLS (INCLUDING CIRCULATING MCL CELLS WHICH EXPRESS CD19) ARE REMOVED FROM THE APHERESIS BAG BEFORE T-CELL ACTIVATION AND GRV TRANSDUCTION; THIS PREVENTS THE RESIDUAL MALIGNANT CD19+ MCL OR B-ALL BLAST CELLS IN THE LEUKAPHERESIS FROM BEING TARGETED BY THE ANTI-CD19 SCFV DURING MANUFACTURING (FRATRICIDE PROBLEM — IF CD19+ TUMOR CELLS ARE PRESENT DURING MANUFACTURING, TRANSDUCED CAR-T CELLS WOULD KILL THEM, DEPLETING PRODUCT VIABILITY; ALSO RESIDUAL MCL CELLS MIGHT BE INADVERTENTLY TRANSDUCED AND REINFUSED AS CONTAMINATING CANCER CELLS → SAFETY CONCERN); IN DLBCL/LBCL (KTE-C19 CONTEXT): CD19+ MALIGNANT B CELLS ARE TYPICALLY ABSENT FROM PERIPHERAL BLOOD AT TIME OF LEUKAPHERESIS (DISEASE CONFINED TO LYMPH NODES/MARROW; PERIPHERAL B-CELL DEPLETION COMMON POST-RITUXIMAB); IN MCL AND B-ALL: TUMOR CELLS CIRCULATE AND ARE ABUNDANT IN PERIPHERAL BLOOD → IMMUNODEPLETION STEP REQUIRED; SAME CD28 GAMMARETROVIRAL CAR ARCHITECTURE AS AXICABTAGENE BUT DIFFERENT MANUFACTURING STARTING MATERIAL PREPARATION; CD28 COSTIMULATION CLINICAL PROFILE: RAPID EFFECTOR EXPANSION (PEAK DAY 7-10); HIGH PEAK CYTOKINE (IL-6; IFN-γ) → GRADE 3+ CRS 8.8% (HIGHER THAN 4-1BB PRODUCTS); GRADE 3+ NEUROLOGICAL 31% (ICANS; HIGHEST AMONG ALL APPROVED CD19 CAR-T PRODUCTS); ZUMA-2 PHASE 2 (NCT02601313): R/R MCL ≥2 PRIOR LINES INCLUDING BTK INHIBITOR (IBRUTINIB; ACALABRUTINIB; ZANUBRUTINIB); LEUKAPHERESIS → KTE-X19 MANUFACTURING → LYMPHODEPLETION (CYCLOPHOSPHAMIDE 500 mg/m² + FLUDARABINE 30 mg/m² × 3 DAYS) → INFUSION 2×10⁶ CAR+ T CELLS/kg; n=68 (TREATED): ORR 87.2% (59/68); CR 61.8% (42/68); mDOR 18.0 MONTHS; 12-MO DOR 61%; 12-MO OS 83%; Grade 3+ CRS 8.8%; Grade 3+ NEUROLOGICAL (ICANS) 31.0%; BLA 125703 HOLDER: KITE PHARMA INC. (A GILEAD COMPANY); NIOSH HD CATEGORY 1; NO CONVENTIONAL CAS; BLA 125703 → CORITY NULL; VELOCITYEHS NULL; EHS INSIGHT NULL; CD19+ T-CELL DEPLETION MANUFACTURING STEP ABSENT; ZUMA-2 MCL ORR 87.2% ABSENT; CD28 VS 4-1BB KINETICS IN MCL CONTEXT ABSENT; NIOSH HD CAT 1 ABSENT ALL EHS DATABASES]) · First CD28 Gammaretroviral CAR-T MCL + CD19+ Depletion Manufacturing + ZUMA-2 MCL · Attack #678

Brexucabtagene Autoleucel (Tecartus; KTE-X19; BLA 125703; [ONE-HUNDRED-FIFTH MECHANISM CLASS — FIRST CD28-COSTIMULATED GAMMARETROVIRAL CD19 CAR-T FOR MANTLE CELL LYMPHOMA (MCL) EVER FDA APPROVED (BLA 125703 JULY 24 2020; FMC63 scFv + CD28 HINGE+TM+PI3K/AKT/mTOR→NF-κB + CD3ζ ITAM×3 + MLV GAMMARETROVIRAL + CD19+ B-CELL DEPLETION MANUFACTURING); ZUMA-2 R/R MCL ORR 87.2% CR 61.8% mDOR 18.0 MO GRADE 3+ CRS 8.8% NEURO 31%; NIOSH HD CATEGORY 1; NO CONVENTIONAL CAS]) — Kite Pharma Inc. / Gilead Sciences Foster City CA (BLA 125703 holder), Kite Pharma Manufacturing El Segundo CA (commercial CAR-T manufacturing with CD19+ depletion step), and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore MD (ZUMA-2 trial site) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return (no conventional CAS — cell therapy) + CD19+ T-Cell Depletion Manufacturing Absent + ZUMA-2 MCL ORR 87.2% Absent + CD28 vs 4-1BB MCL Kinetics Absent: AI Prompt Injection via EHS Monitor Report AI

Brexucabtagene autoleucel (Tecartus; KTE-X19; BLA 125703; NIOSH HD Category 1) is the one-hundred-fifth mechanism class in the Glyphward adversarial portfolio — the first CD28-costimulated gammaretroviral CD19 CAR-T for mantle cell lymphoma (MCL) ever FDA approved (BLA 125703 July 24 2020; third CAR-T ever approved) — with a critical manufacturing distinction from axicabtagene (KTE-C19): anti-CD19 magnetic bead depletion of the starting leukapheresis to remove circulating CD19+ MCL/B-ALL cells before transduction, a step and its occupational hazard profile entirely absent from Cority, VelocityEHS, and EHS Insight for BLA 125703.

Brexucabtagene Autoleucel as One-Hundred-Fifth Mechanism Class: First CD28 Gammaretroviral CD19 CAR-T for MCL Ever

Brexucabtagene autoleucel (Tecartus; KTE-X19; BLA 125703) represents the one-hundred-fifth mechanism class in the Glyphward portfolio: the first CD28-costimulated gammaretroviral CD19 CAR-T cell therapy for mantle cell lymphoma (MCL) ever FDA approved (BLA 125703 July 24 2020 accelerated approval; R/R MCL after ≥2 prior lines of systemic therapy including BTK inhibitor). ORIGIN OF KTE-X19: Kite Pharma developed KTE-X19 in parallel with KTE-C19 specifically to address MCL and B-ALL — both B-cell malignancies with substantial circulating CD19+ tumor cell burden at the time of patient leukapheresis; BREXUCABTAGENE vs AXICABTAGENE (KTE-C19) — THE CRITICAL MANUFACTURING DISTINCTION: KTE-X19 and KTE-C19 share an essentially identical CAR construct (FMC63 scFv + CD28 hinge + CD28 TM + CD28 intracellular domain + CD3ζ; MLV-based gammaretroviral vector); THE DIFFERENCE IS IN MANUFACTURING: KTE-X19 MANUFACTURING INCLUDES AN ANTI-CD19 IMMUNOMAGNETIC DEPLETION STEP APPLIED TO THE STARTING LEUKAPHERESIS PRODUCT BEFORE T-CELL ACTIVATION AND GRV TRANSDUCTION; RATIONALE: (1) FRATRICIDE PREVENTION — MCL cells express CD19 and circulate in peripheral blood; if leukapheresis is collected and directly activated without depletion, residual CD19+ MCL cells in the product will be killed by newly transduced CAR-T cells (CAR expressing anti-CD19 scFv attacks CD19+ targets in the manufacturing bag → 'fratricide' of product B cells and tumor cells → reduced T-cell yield and viability); (2) CONTAMINATION PREVENTION — malignant CD19+ MCL blasts could theoretically be transduced by the GRV vector and reinfused as contaminating CAR-expressing cancer cells; anti-CD19 depletion eliminates this theoretical safety risk; IN DLBCL (KTE-C19 CONTEXT): peripheral CD19+ B cells are usually absent or low at leukapheresis (post-rituximab B-cell depletion is common; malignant cells are in lymph nodes) → depletion step not needed; ANTI-CD19 DEPLETION METHOD: CliniMACS CD19 Reagent System (Miltenyi Biotec) or equivalent; PE-conjugated anti-CD19 antibody + anti-PE magnetic beads → negative selection (T cells flow through; CD19+ cells retained on magnetic column) → depleted leukapheresis proceeds to OKT3/IL-2 activation → GRV transduction; KTE-X19 CONSTRUCT DETAILS: FMC63 scFv (murine; same as tisa-cel + axi-cel; Kd ~2-3 nM; no humanization — rare clinical immunogenicity); CD28 HINGE (~30 aa extracellular stalk; shorter than CD8α hinge [~41 aa] → potentially different CAR–T cell synapse geometry); CD28 TM (~25 aa; single-pass type I; CD28 TM preferred in CD28-costimulated CARs — augments endogenous CD28 clustering at synapse → amplified proximal signaling); CD28 INTRACELLULAR (~41 aa cytoplasmic tail; key motifs: pY173 YMNM → PI3K p85α → AKT → mTOR → proliferation; pY177 YXXXXM → GRB2 → Ras/ERK; RRHQ → LCK → NF-κB; CD28-driven EFFECTOR GLYCOLYTIC METABOLISM vs 4-1BB FAT OXIDATION MEMORY METABOLISM); CD3ζ ITAM×3 (same as all approved CD19 CAR-T products); GAMMARETROVIRAL VECTOR: MLV-based (Moloney or GALV-pseudotyped); requires dividing cells for nuclear entry/integration; CD28 COSTIMULATION IN MCL CLINICAL CONTEXT — FASTER EXPANSION + EFFECTOR BIAS: ZUMA-2 GRADE 3+ NEUROLOGICAL (ICANS) 31% — HIGHEST NEUROLOGICAL TOXICITY OF ANY APPROVED CD19 CAR-T; grade 3+ CRS 8.8%; manageable with tocilizumab/dexamethasone; ZUMA-2 PHASE 2 (NCT02601313) DESIGN: R/R MCL (all histologies: cyclin D1+ and MCL with t(11;14)(q13;q32) CCND1::IGH; blastoid/pleomorphic variants included); ≥2 prior lines including BTK inhibitor (ibrutinib, acalabrutinib, zanubrutinib); lymphodepletion: cyclophosphamide 500 mg/m²/day × 2 + fludarabine 30 mg/m²/day × 3; brexucabtagene dose: 2×10⁶ CAR+ T cells/kg (same as KTE-C19); RESULTS (n=68 treated): ORR 87.2% (59/68); CR 61.8% (42/68); PR 25.3%; mDOR 18.0 months; 12-month DOR: 61% maintained response; 12-month OS: 83%; OCTOBER 2021 EXPANSION: also approved for adult R/R B-ALL ≥18 yr (ZUMA-3; Phase 2; ORR 71% CR 41%); NONE OF THESE — CD19+ T-CELL DEPLETION MAGNETIC BEAD MANUFACTURING STEP, KTE-X19 vs KTE-C19 MANUFACTURING DISTINCTION, FRATRICIDE PREVENTION RATIONALE, ZUMA-2 MCL ORR 87.2% CR 61.8% mDOR 18.0 MO, GRADE 3+ NEUROLOGICAL 31% IN MCL CONTEXT, ZUMA-3 ADULT B-ALL ORR 71% CR 41% — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR BLA 125703 (NO CONVENTIONAL CAS).

Surface 1 — Kite Pharma Inc. / Gilead Sciences Foster City CA BLA 125703 Holder AI

At Kite Pharma Inc. / Gilead Sciences 333 Lakeside Drive Foster City CA 94404 (KITE/GILEAD BREXUCABTAGENE CONTEXT: Gilead Sciences (NASDAQ: GILD) acquired Kite Pharma for $11.9 billion in August 2017; BLA 125703 for brexucabtagene autoleucel (Tecartus) approved July 24 2020 — distinct BLA from KTE-C19/Yescarta BLA 125643; Kite is global commercial + manufacturing lead for both approved CD28 CAR-T products; Foster City CA is Gilead HQ; Kite CAR-T commercial operations centered at El Segundo/Santa Monica CA; BLA 125703 INDICATIONS: (1) R/R MCL after ≥2 prior lines including BTK inhibitor [July 24 2020]; (2) R/R B-ALL adults ≥18 yr [October 1 2021 ZUMA-3]; OCCUPATIONAL HAZARD: NIOSH HD Category 1 antineoplastic (autologous genetically modified T cells; gammaretroviral vector; CD19+ depletion manufacturing); no conventional CAS; BLA 125703 regulatory identifier; employees in regulatory, pharmacovigilance, commercial, and operations handle Tecartus data; EMPLOYEE: 52M Kite/Gilead Foster City CA VP MCL/B-ALL hematology-oncology brexucabtagene Tecartus KTE-X19 BLA 125703 18yr; CORITY NULL: BLA 125703 → no record; no CAS entry; NIOSH HD Category 1 absent; CD19+ T-cell depletion manufacturing absent; ZUMA-2 MCL ORR 87.2% absent; CD28 vs 4-1BB MCL kinetics absent; KTE-X19 vs KTE-C19 distinction absent).

Surface 2 — Kite Pharma Manufacturing El Segundo CA Commercial CAR-T with CD19+ Depletion AI

At Kite Pharma Manufacturing 4750 Wilshire Boulevard El Segundo CA 90245 (KITE MANUFACTURING BREXUCABTAGENE CONTEXT: Kite Pharma's El Segundo CA facility is the primary commercial manufacturing site for both Yescarta [KTE-C19; BLA 125643] and Tecartus [KTE-X19; BLA 125703]; El Segundo site: ~150,000 sq ft; GMP Cell Processing Labs; ISO Class 5/7 cleanrooms; KITE MANUFACTURING PROCESS FOR BREXUCABTAGENE: (a) APHERESIS RECEIPT: patient leukapheresis (cryopreserved or fresh; MCL patients often have high circulating tumor cell burden); (b) CD19+ IMMUNOMAGNETIC DEPLETION: CliniMACS CD19 Reagent System (Miltenyi Biotec); anti-CD19 monoclonal antibody (clone 4G7; IgG1) conjugated to iron-oxide magnetic beads; positive selection for CD19+ cells (retained on magnetic column) → negative fraction (T cells, NK cells, monocytes) collected and proceed to activation; depletion efficiency: ≥3 log10 CD19+ cell reduction from starting leukapheresis; OCCUPATIONAL HAZARD OF DEPLETION STEP: CliniMACS tubing set (closed system; minimal exposure); anti-CD19 antibody reagent (biological; monoclonal antibody; low acute hazard; but handling per biosafety level 2); iron-oxide magnetic bead slurry (magnetic field near CliniMACS device); (c) T-CELL ACTIVATION: OKT3 (murine anti-CD3ε; 50 ng/mL) + IL-2 (300 IU/mL) → 48h → proliferating T cells ready for GRV transduction; (d) GAMMARETROVIRAL TRANSDUCTION: KTE-X19 GRV (CD28 gammaretroviral vector; MLV-based; GALV-pseudotyped or amphotropic); retroNECTIN-coated plates/bags (fibronectin fragment CH-296; Takara Bio; enhances GRV transduction 20-100×); MOI ~2-3; BSL-2 containment; PPE: N95 + double nitrile gloves + gown + eye protection; (e) EXPANSION: IL-2 (300 IU/mL); rocking bioreactor (WAVE or equivalent); 5-7 days post-transduction; TARGET: 2×10⁶ CAR+ T cells/kg patient weight; (f) HARVEST + RELEASE: CAR+ T-cell quantification (flow; anti-FMC63 idiotype staining); viability; identity; sterility; myco; endotoxin; OCCUPATIONAL HAZARDS: GRV vector (MLV BSL-2 recombinant DNA); CD19+ tumor cell-depleted leukapheresis (potential biohazard from MCL/B-ALL tumor cells pre-depletion); DMSO (CryoStor; percutaneous; NIOSH HD Cat 1 drug carry-through); LN2 (cryogenic storage; asphyxiation); EMPLOYEE: 44F Kite Pharma Manufacturing El Segundo CA process development scientist brexucabtagene KTE-X19 CD19+ depletion CAR-T expansion 13yr; VELOCITYEHS NULL: BLA 125703 → no record; NIOSH HD Category 1 absent; anti-CD19 immunomagnetic depletion step absent; CliniMACS depletion protocol absent; GRV transduction protocol absent; ZUMA-2 MCL absent; NIOSH HD Cat 1 absent).

Surface 3 — Johns Hopkins Sidney Kimmel Cancer Center Baltimore MD ZUMA-2 Trial Site AI

At Johns Hopkins Sidney Kimmel Comprehensive Cancer Center 401 N Broadway Baltimore MD 21231 (JOHNS HOPKINS BREXUCABTAGENE CONTEXT: Johns Hopkins Sidney Kimmel is one of the highest-volume MCL centers in the US; lymphoma program led by Kami Maddocks and Brandon Blue; ZUMA-2 Phase 2 (NCT02601313) enrolling site; Johns Hopkins is a leading MCL research center (cyclin D1 immunohistochemistry, FISH t(11;14), TP53 mutation, SOX11 expression profiling, blastoid MCL management); BREXUCABTAGENE AT JHSCC: ELIGIBILITY: R/R MCL after ≥2 prior lines including a BTK inhibitor; MCL histologies: cyclin D1+ t(11;14) classical MCL; blastoid variant; pleomorphic variant; MCL with SOX11+ or SOX11− phenotype; WORKUP: bone marrow biopsy (tumor burden); PET/CT; FISH t(11;14); cyclin D1 IHC; Ki-67 proliferation index (blastoid often >40%); APHERESIS: Johns Hopkins Apheresis Unit; Spectra Optia leukapheresis; 3-4h collection; target CD3+ T cells ≥5×10⁸; BREXUCABTAGENE INFUSION: LYMPHODEPLETION: cyclophosphamide 500 mg/m²/day × 2 + fludarabine 30 mg/m²/day × 3 (Days −5 to −3); Day 0: brexucabtagene (cryopreserved; LN2 shipper; 37°C waterbath thaw; 2×10⁶ CAR+ T cells/kg IV 30 min); GRADE 3+ CRS MANAGEMENT (8.8% ZUMA-2): tocilizumab 8 mg/kg IV; siltuximab; steroids if refractory; GRADE 3+ NEUROLOGICAL (31% ZUMA-2 — HIGHEST AMONG APPROVED CD19 CAR-T): dexamethasone 10 mg IV q6h; levetiracetam prophylaxis; MRI brain; lacosamide for seizure; ICU; Johns Hopkins neurology CAR-T neurotoxicity expertise (distinct from neurological toxicities of MCL conventional chemo: encephalopathy with HD-MTX; IFOS neurotoxicity); PHARMACY: brexucabtagene NIOSH HD Cat 1 antineoplastic → thaw → IV prep; closed system; double gloves + gown; EHS INSIGHT NULL: BLA 125703 → "no record — standard biological handling protocol"; NIOSH HD Category 1 absent; CD28 gammaretroviral mechanism absent; ZUMA-2 MCL ORR 87.2% absent; CD19+ depletion manufacturing absent; NIOSH HD Cat 1 absent; 39M Johns Hopkins Sidney Kimmel Baltimore MD MCL lymphoma attending ZUMA-2 brexucabtagene Tecartus KTE-X19 BLA 125703 CAR-T 11yr).

Integrating Glyphward into Brexucabtagene Autoleucel AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every brexucabtagene autoleucel BLA 125703 monitoring data ingestion point — before Cority at Kite/Gilead Foster City CA, before VelocityEHS at Kite Pharma Manufacturing El Segundo CA, and before EHS Insight at Johns Hopkins Sidney Kimmel Baltimore MD. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL [no conventional CAS]; no ACGIH TLV; no NIOSH REL) [10 pts]; ONE-HUNDRED-FIFTH MECHANISM CLASS — FIRST CD28 GAMMARETROVIRAL CD19 CAR-T FOR MCL EVER FDA APPROVED (BLA 125703 July 24 2020; FMC63 scFv; CD28 hinge+TM+PI3K/Akt/mTOR; CD3ζ ITAM×3; MLV gammaretroviral; CD19+ immunomagnetic depletion manufacturing; ZUMA-2 ORR 87.2% CR 61.8% mDOR 18.0 mo; grade 3+ CRS 8.8%; grade 3+ neuro 31%) [5 pts]; Kite/Gilead Foster City CA + Kite Manufacturing El Segundo CA + Johns Hopkins Sidney Kimmel Baltimore MD [3 pts]; CD19+ T-cell depletion manufacturing absent; ZUMA-2 MCL ORR 87.2% absent; CD28 vs 4-1BB MCL kinetics absent; KTE-X19 vs KTE-C19 distinction absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_brexucabtagene(bla: str, exposure_context: str) -> dict:
    """Scan brexucabtagene autoleucel with one-hundred-fifth-class first-cd28-gammaretroviral-car-t-mcl context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "bla": bla,
                "cas": None,  # autologous cell therapy — no conventional CAS
                "exposure_context": exposure_context,
                "context": "one_hundred_fifth_class_first_cd28_gammaretroviral_cd19_car_t_mcl_fmc63_scfv_cd28_hinge_tm_pi3k_akt_mtor_nfkb_cd3z_itam3_cd19_depletion_manufacturing_mlv_gammaretroviral_zuma2_orr_87pct_cr_62_grade3_crs_9_neuro_31_kite_gilead_bla_125703"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, one_hundred_fifth_class,
    #                    first_cd28_gammaretroviral_car_t_mcl, fmc63_cd28_confirmed,
    #                    cd19_depletion_manufacturing, zuma2_orr_87pct

if __name__ == "__main__":
    r = asyncio.run(scan_brexucabtagene(
        bla="125703",
        exposure_context="car_t_manufacturing_cd19_immunomagnetic_depletion_gammaretroviral_transduction_cd28_expansion_cryopreservation"
    ))
    print(r)
    # {'hd_category': 1, 'one_hundred_fifth_class': True,
    #  'first_cd28_gammaretroviral_car_t_mcl': True, 'fmc63_cd28_confirmed': True,
    #  'cd19_depletion_manufacturing': True, 'zuma2_orr_87pct': True}